Compare OCGN & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCGN | PNNT |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 397.7M |
| IPO Year | 2014 | 2007 |
| Metric | OCGN | PNNT |
|---|---|---|
| Price | $1.58 | $5.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $7.00 | $5.85 |
| AVG Volume (30 Days) | ★ 3.8M | 752.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | ★ 18.64% |
| EPS Growth | ★ 31.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $5.04 |
| 52 Week High | $1.96 | $7.53 |
| Indicator | OCGN | PNNT |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 25.42 |
| Support Level | $1.38 | $5.04 |
| Resistance Level | $1.47 | $5.22 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 94.64 | 3.47 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.